Enzymes and pharmacogenetics of cardiovascular drugs

Clinica Chimica Acta

Volumn 381, Issue 1, 2007, Pages 26-31

  Siest, Gérard ^a   Jeannesson, Elise ^a   Visvikis Siest, Sophie ^a  

^a INSERM   (France)

Author keywords

Cardiovascular drugs; Cytochrome; P450; Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

ABC TRANSPORTER; AMIODARONE; CANDESARTAN; CAPTOPRIL; CARDIOVASCULAR AGENT; CLONIDINE; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPYRIDAMOLE; DISOPYRAMIDE; ENALAPRIL; ENCAINIDE; FLECAINIDE; GUANOXAN; INDAPAMIDE; IRBESARTAN; LIDOCAINE; LOSARTAN; MEXILETINE; MULTIDRUG RESISTANCE PROTEIN 1; PRAJMALINE; PRAZOSIN; PROCAINAMIDE; PROPAFENONE; QUINIDINE; UNINDEXED DRUG;

BLOOD PRESSURE; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME SUBSTRATE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIPID METABOLISM; PHARMACOGENETICS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT RESPONSE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; HUMANS; PHARMACOGENETICS;

EID: 34248140809     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.014     Document Type: Review

References (25)

1. Siest G., Jeannesson E., Berrahmoune H., et al. Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics 5 (2004) 779-802
2. Siest G., Marteau J.B., Maumus S., et al. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers. Eur J Pharmacol 527 (2005) 1-22
3. Nelson D.R., Zeldin D.C., Hoffman S.M., Maltais L.J., Wain H.M., and Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14 (2004) 1-18
4. Linder M.W., Prough R.A., and Valdes Jr. R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 43 (1997) 254-266
5. Bodin L., Verstuyft C., Tregouet D.A., et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106 (2005) 135-140
6. D'Andrea G., D'Ambrosio R.L., Di Perna P., et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
7. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 (2000) 3473-3478
8. Kajinami K., Brousseau M.E., Ordovas J.M., and Schaefer E.J. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol 93 (2004) 1046-1050
9. Thompson J.F., Man M., Johnson K.J., et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5 (2005) 352-358
10. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 234 (2006) 4-33
11. Maeda K., Ieiri I., Yasuda K., et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin Pharmacol Ther 79 (2006) 427-439
12. Niemi M., Arnold K.A., Backman J.T., et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics 16 (2006) 801-808
13. Schmitz G., and Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 44 (2006) 75-89
14. Chasman D.I., Posada D., Subrahmanyan L., Cook N.R., Stanton Jr. V.P., and Ridker P.M. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 (2004) 2821-2827
15. Simon J.S., Karnoub M.C., Devlin D.J., et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 86 (2005) 648-656
16. Hegele R.A., Guy J., Ban M.R., and Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 4 (2005) 16
17. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
18. Struthers A.D., Anderson G., MacFadyen R.J., Fraser C., and MacDonald T.M. Nonadherence with ACE inhibitors is common and can be detected in clinical practice by routine serum ACE activity. Congest Heart Fail 7 (2001) 43-46
19. Rice G.I., Jones A.L., Grant P.J., Carter A.M., Turner A.J., and Hooper N.M. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48 (2006) 914-920
20. Maurer H.H., Kraemer T., and Arlt J.W. Screening for the detection of angiotensin-converting enzyme inhibitors, their metabolites, and AT II receptor antagonists. Ther Drug Monit 20 (1998) 706-713
21. Chevillard C., Jouquey S., Bree F., et al. Compared properties of trandolapril, enalapril, and their diacid metabolites. J Cardiovasc Pharmacol 23 Suppl 4 (1994) S11-S15
22. Schelleman H., Klungel O.H., van Duijn C.M., et al. Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. Br J Clin Pharmacol 59 (2005) 483-485
23. Boomsma F., Pedersen-Bjergaard U., Agerholm-Larsen B., et al. Association between plasma activities of semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in patients with type 1 diabetes mellitus. Diabetologia 48 (2005) 1002-1007
24. McNamara D.M., Holubkov R., Postava L., et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2019-2026
25. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/ (1 Dec 2006).